Mounjaro (tirzepatide) is a GLP-1/GIP receptor agonist approved by the FDA for type 2 diabetes. Kaiser Permanente covers it on most commercial and employer plans, but only for that specific diagnosis. Coverage rules vary by region, plan type, and medical condition.
Kaiser’s formulary places Mounjaro at Tier 3 in Northern California and Tier 4 in Southern California for diabetes. Prior authorization is required on every plan. Step therapy applies, meaning a patient must trial Ozempic first. Medicare Part D through Kaiser does not list Mounjaro on its 2025 formulary at all.
This guide breaks down exactly when Kaiser covers Mounjaro, what the prior authorization requires, what it costs, and what options exist when coverage is denied. By the end, you’ll know exactly what steps to take for your specific plan.
Does Kaiser Cover Mounjaro?
Kaiser Permanente covers Mounjaro for type 2 diabetes on most commercial and employer plans, but not for weight loss under any plan or line of business. Coverage requires prior authorization and step therapy on every regional plan. The answer depends entirely on why the medication is being prescribed.
But here is the thing most people miss: the FDA approves Mounjaro only for type 2 diabetes. The weight-loss version of the same active ingredient, tirzepatide, is sold under a different brand name, Zepbound. Kaiser treats these as separate drugs with separate coverage rules.
Medicare Part D through Kaiser is a different situation. Mounjaro does not appear on Kaiser’s 2025 Medicare Part D formulary. Ozempic covers the diabetes indication on that plan instead. If you have Kaiser Medicare, you would need to request a non-formulary exception.
Is Mounjaro Covered for Type 2 Diabetes?
Yes. Kaiser covers Mounjaro for type 2 diabetes on all commercial and employer plans, with prior authorization and a semaglutide-first step-therapy requirement. The SURPASS-2 trial (Frias et al., 2021, NEJM) showed A1C reductions of 2.0 to 2.3 percentage points at the highest dose, the strongest A1C lowering of any approved diabetes drug.
The clinical bar is clear. A patient needs a documented type 2 diabetes diagnosis with an ICD-10 code, an A1C of 7.0 or higher, and evidence of a prior metformin trial unless metformin is contraindicated. The prescriber must submit all three pieces of documentation together for the PA to be reviewed.
Regional tier differences matter for cost. NorCal plans place Mounjaro at Tier 3. SoCal plans place it at Tier 4. A higher tier means a higher copay, so out-of-pocket cost varies by region even when the drug is covered.
Is Mounjaro Covered for Weight Loss?
No. Kaiser Permanente does not cover Mounjaro for weight loss on any plan, including commercial, employer, Medicare, or Medi-Cal. Mounjaro holds FDA approval only for type 2 diabetes. Off-label weight-loss use is explicitly excluded from all Kaiser formularies.
The drug to know for weight loss is Zepbound. Zepbound contains the same active ingredient, tirzepatide, but carries a separate FDA approval for obesity and obstructive sleep apnea. Kaiser’s P&T committee evaluates Zepbound under different, more restrictive criteria than Mounjaro.
Medi-Cal through Kaiser tightened rules further. California Medicaid excluded weight-loss GLP-1 medications effective January 1, 2026. So patients on Kaiser Medi-Cal have no path to tirzepatide for obesity through that plan at all.
How Does Kaiser’s Prior Authorization for Mounjaro Work?
Kaiser’s prior authorization for Mounjaro is an internal process managed by Kaiser’s own Pharmacy and Therapeutics committee, not an external PBM, which means criteria are specific to Kaiser’s formulary design. The PA must come from a Kaiser prescriber who documents medical necessity using Kaiser-required forms.
In plain English: Kaiser writes its own rules. Other insurers might use Express Scripts or CVS Caremark. Kaiser does not. This matters because appeal standards and denial reasoning are Kaiser-specific, not industry-standard language from a pharmacy benefit manager.
The PA process involves three core steps. The prescriber submits a request with clinical documentation. Kaiser’s pharmacy team reviews it against formulary criteria. An approval or denial is issued, typically within standard turnaround times unless expedited review is requested.
What Are the Requirements to Get Approved?
Mounjaro prior authorization at Kaiser requires five documented criteria: a type 2 diabetes diagnosis with ICD-10 code, an A1C of 7.0 or higher, a prior metformin trial, evidence of a semaglutide step-therapy attempt, and prescriber documentation on Kaiser’s PA form.
Key requirements to meet:
- Type 2 diabetes diagnosis with ICD-10 documentation
- A1C of 7.0 or higher (or 6.5 to 6.9 with completed metformin trial)
- Prior metformin trial unless contraindicated with clinical reason documented
- Trial or documented intolerance of semaglutide (Ozempic)
- Patient age 18 or older
Missing any one of these five criteria results in a denial. The most common gap is the step-therapy documentation. A prescriber who submits the PA without proof that the patient tried Ozempic first will receive a formulary exclusion denial, not a medical necessity denial. Those are handled differently in the appeal process.
What Is Step Therapy and Why Does Kaiser Require It?
Step therapy is a formulary management tool that requires patients to try a lower-tier or lower-cost drug before Kaiser approves the requested medication. For Mounjaro, both NorCal and SoCal plans require a semaglutide-first step, meaning Ozempic must be tried before Mounjaro is approved.
Here is why that matters. Ozempic is a Tier 2 drug at Kaiser. Mounjaro is Tier 3 or 4. Step therapy protects formulary integrity and manages costs. A patient who cannot tolerate Ozempic due to GI side effects, or who fails to reach A1C goals on Ozempic, meets the step-therapy requirement with proper documentation from the prescriber.
The prescriber’s role is critical here. Kaiser’s PA form includes a step-therapy section where the clinician documents what happened on Ozempic. Without a complete and accurate entry in that section, the PA is returned as incomplete. The fastest path to approval is a prescriber who knows exactly what Kaiser’s form requires.
How Much Does Mounjaro Cost with Kaiser?
Mounjaro costs at Kaiser depend on the plan tier, the member’s deductible status, and whether a Lilly savings card applies. NorCal plans set Mounjaro at Tier 3 and SoCal at Tier 4, which translates to different copays per plan design. The Lilly savings card reduces cost to $25 per month for commercially insured patients only.
The Lilly savings card is not available for Medicare or Medi-Cal beneficiaries. For commercial Kaiser plan members, the card brings the monthly cost to $25 when coverage applies. Without coverage, the card sets cost at $499 per month, which is below retail but still significant.
What Does Mounjaro Cost at Each Tier?
Tier placement determines the copay structure. Tier 3 at Kaiser NorCal and Tier 4 at Kaiser SoCal means Mounjaro carries a mid-to-high copay, with exact amounts set by the member’s specific plan design and deductible stage.
Cost comparison by scenario:
| Scenario | Estimated Monthly Cost |
| Kaiser commercial with coverage + Lilly card | $25 |
| Kaiser commercial with coverage, no card | Plan copay (varies) |
| Lilly card without coverage | $499 |
| No insurance, no card (retail) | $1,000+ |
| Compounded tirzepatide (off-label, not branded) | From $149 |
Members still in their deductible phase pay the full negotiated rate before copays apply. A Kaiser plan with a $2,000 deductible means the member pays the full Tier 3 rate until that threshold is met. Checking deductible status before requesting the PA saves surprises at the pharmacy.
How Much Does Mounjaro Cost Without Insurance?
Without insurance, Mounjaro retails at over $1,000 per month. The full retail price for a monthly Mounjaro supply has consistently exceeded $1,000, making it one of the most expensive diabetes medications available without a coverage benefit.
Ready to speed things up? Get a proven weight loss plan built around the latest science on tirzepatide and metabolic health, without the insurance maze.
Compounded tirzepatide is available from some pharmacies starting around $149 per month. But here is what no one tells you: compounded tirzepatide is not the same as branded Mounjaro. The FDA previously allowed compounding pharmacies to make tirzepatide during a national shortage. That shortage has been resolved. Pharmacies and outsourcing facilities are no longer permitted to compound or dispense compounded GLP-1 medications, including tirzepatide. Any compounded product currently offered operates in a legally uncertain space.
Which GLP-1 Medications Does Kaiser Cover?
Kaiser’s 2026 formulary includes six GLP-1 medications: Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda, and Rybelsus, each approved for different indications and placed at different tiers. Diabetes drugs (Ozempic, Mounjaro) are covered more consistently than weight-loss drugs, which carry BMI and comorbidity requirements.
And this is where it gets interesting. Some Kaiser plans cover Mounjaro for diabetes but not Zepbound for obesity. A patient with both type 2 diabetes and obesity might qualify for Mounjaro under the diabetes pathway, which then delivers the weight-loss benefit of tirzepatide without needing the obesity-specific Zepbound criteria.
Does Kaiser Cover Ozempic?
Yes. Ozempic (semaglutide) is covered for type 2 diabetes on every Kaiser plan in 2026, including Medicare Part D, at Tier 2 with prior authorization. Kaiser’s Medicare formulary lists Ozempic where it does not list Mounjaro, making Ozempic the primary GLP-1 option for Kaiser Medicare members with diabetes.
The PA for Ozempic uses the same diagnostic framework. It requires a type 2 diabetes diagnosis with ICD-10 documentation, an A1C of 7.0 or higher (or 6.5 to 6.9 with a prior metformin trial), and patient age 18 or older. The SUSTAIN trial program (Lancet and NEJM, 2017 through 2019) is the clinical reference Kaiser’s P&T committee uses when evaluating Ozempic medical necessity.
Does Kaiser Cover Zepbound Instead of Mounjaro?
Some Kaiser plans cover Zepbound for weight loss or obstructive sleep apnea, but not all. Zepbound coverage requires a BMI of 35 kilograms per square meter (kg/m2) or higher, or a BMI of 30 kg/m2 or higher with a severe comorbidity, plus completion of a 12-month Kaiser weight management program in most regions.
The OSA pathway is different. For obstructive sleep apnea, Kaiser regions that added the SURMOUNT-OSA criteria in 2026 require a confirmed apnea-hypopnea index (AHI) of 15 or higher on polysomnography, plus a BMI of 30 kg/m2 or higher. The 12-month weight management program requirement is typically waived under the OSA pathway.
So what does that mean for you? If weight loss is the goal and you have OSA documentation, the Zepbound OSA pathway may be faster to approve than the obesity pathway. A sleep study showing AHI of 15 or higher, combined with BMI documentation, positions a patient well for the 2026 OSA criteria.
What Happens If Kaiser Denies Mounjaro Coverage?
A Kaiser denial for Mounjaro triggers a formal appeals process with multiple levels: an internal appeal reviewed by Kaiser’s medical team, followed by an Independent Medical Review (IMR) through the state if the internal appeal fails. Most denials are for step-therapy or documentation gaps, not for absolute formulary exclusions.
The good news? Most denials at the initial level are reversible. Step-therapy denials often resolve when the prescriber submits documentation of the Ozempic trial. Medical necessity denials require more clinical detail but carry a reasonable appeal success rate when the underlying diagnosis is well-documented.
How Long Does the Kaiser Appeal Process Take?
The full Kaiser appeal timeline, from initial denial through a final Independent Medical Review decision, runs roughly 4 to 5 months. Expedited appeals compress that timeline to 10 to 14 days end to end when clinical urgency is documented.
Appeal process steps in order:
- Request an internal appeal within 60 days of the denial notice
- Submit prescriber’s clinical documentation and supporting evidence
- Kaiser internal medical team reviews the case (standard: 30 days; expedited: 72 hours)
- If denied internally, request an Independent Medical Review through the state
- IMR decision is binding on Kaiser and typically issued within 30 to 45 days
Expedited appeal eligibility requires a prescriber attestation that delay would seriously jeopardize the patient’s health. Accepted triggers include uncontrolled diabetes, established cardiovascular disease, severe OSA, or a recent cardiovascular event. Without that attestation, the standard timeline applies.
What Are the Alternatives If the Appeal Fails?
When appeals fail, four practical alternatives exist. The most clinically equivalent option is Ozempic for type 2 diabetes patients, since it is already on Kaiser’s formulary at Tier 2 and requires a similar PA process without the step-therapy barrier.
Alternatives to consider:
- Ozempic (semaglutide) for T2D patients, covered on all Kaiser plans including Medicare
- Zepbound for obesity or OSA patients who meet BMI and comorbidity criteria
- Trulicity (dulaglutide) or Jardiance (empagliflozin) as lower-tier diabetes alternatives
- Discount cards like SingleCare or GoodRx to reduce out-of-pocket cost without insurance
The nutritionists at Eat Proteins often work with clients navigating exactly this situation. The diet and protein strategy around a GLP-1 medication matters as much as the drug itself. Whether a patient is on Ozempic, Mounjaro, or nothing at all, the nutritional framework drives long-term results.
How Do You Check Your Kaiser Plan’s Mounjaro Coverage?
Checking Kaiser coverage for Mounjaro requires three specific steps: verifying the current regional formulary, working with a Kaiser prescriber on PA documentation, and confirming formulary year status directly with Kaiser member services using your member ID.
Here is why this matters. Kaiser operates across multiple regions, each with its own formulary. A drug covered in the Northwest region may not appear in the NorCal or SoCal formulary. And formularies update annually. What was true in 2024 may differ in 2026.
What Steps Should You Take to Verify Coverage?
Three steps confirm Mounjaro coverage status accurately. Step one is checking the Kaiser drug formulary list for your specific region on the Kaiser member portal, which shows tier placement, PA requirements, and step-therapy flags.
Steps to verify your coverage:
- Log into the Kaiser member portal and search the drug formulary for your region by entering “Mounjaro” or “tirzepatide”
- Bring the formulary result to your Kaiser prescriber and ask them to initiate a PA with full step-therapy documentation
- Call Kaiser member services using the number on your insurance card and confirm coverage, formulary year, and any quantity limits that apply to your specific plan
Do not rely on a general Kaiser website search. The formulary differs by region and by plan type (commercial, Medicare, Medi-Cal). Using your member ID when calling member services ensures you get information specific to your plan, not a general policy overview that may not apply to your benefits.
Want Your Free Weight Loss Plan from Eat Proteins?
You have the science. Now you need the plan. Whether Kaiser covers Mounjaro for you or not, the nutritional strategy around GLP-1 medications, protein intake, and metabolic health determines how far your results actually go. Our coaches at Eat Proteins have built a free 7-day plan around exactly these principles, sent straight to your inbox.
Most people get the drug approved and then wing the diet. That is where the results stall. What you eat, how much protein you hit daily, and when you eat around your injection schedule all compound the drug’s effect. Miss that piece, and you are leaving a significant portion of the benefit on the table.
Get the free plan now. It takes 30 seconds to sign up and the first week of guidance lands immediately. No upsell. No pressure. Just the structure our nutritionists at Eat Proteins built for clients on GLP-1 protocols, available to you free.